相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Burden of liver diseases in the world
Sumeet K. Asrani et al.
JOURNAL OF HEPATOLOGY (2019)
Identifying factors affecting the pharmacokinetics of voriconazole in patients with liver dysfunction: A population pharmacokinetic approach
Dan Tang et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2019)
Invasive pulmonary aspergillosis in cirrhotic patients: analysis of a 10-year clinical experience
Eric Levesque et al.
ANNALS OF INTENSIVE CARE (2019)
Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients
Jamie John et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
Population Pharmacokinetics of Voriconazole and Optimization of Dosage Regimens Based on Monte Carlo Simulation in Patients With Liver Cirrhosis
Qiu-xia Ren et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Voriconazole therapeutic drug monitoring: Factors associated with supratherapeutic and subtherapeutic voriconazole concentrations
Haisheng You et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2018)
Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: A multicenter study
Taotao Wang et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2018)
A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis
T. Wang et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2018)
Invasive aspergillosis in patients with underlying liver cirrhosis: a prospective cohort study
Juergen Prattes et al.
MEDICAL MYCOLOGY (2017)
Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients
Zi-Wei Li et al.
THERAPEUTIC DRUG MONITORING (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy
B. Moriyama et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES
Adeel A. Butt et al.
CLINICAL INFECTIOUS DISEASES (2017)
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2016)
Determination of a suitable voriconazole pharmacokinetic model for personalised dosing
David A. J. McDougall et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2016)
The Impact of Model-Misspecification on Model Based Personalised Dosing
David A. J. McDougall et al.
AAPS JOURNAL (2016)
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
Thomas F. Patterson et al.
CLINICAL INFECTIOUS DISEASES (2016)
Early invasive fungal infections and colonization in patients with cirrhosis admitted to the intensive care unit
E. Theocharidou et al.
CLINICAL MICROBIOLOGY AND INFECTION (2016)
Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy
Rajendra S. Kadam et al.
CLINICAL PHARMACOKINETICS (2016)
Utility of voriconazole therapeutic drug monitoring: a meta-analysis
Me-Linh Luong et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis
Haiying Jin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Variations of pharmacokinetics of drugs in patients with cirrhosis
M. A. Pena et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)
Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients-an evidence-based approach
Meinolf Karthaus et al.
ANNALS OF HEMATOLOGY (2015)
Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections
Taotao Wang et al.
PHARMACOTHERAPY (2015)
Fungal colonisation is Associated with Increased Mortality in Medical Intensive Care Unit Patients with Liver Cirrhosis
Tobias Lahmer et al.
MYCOPATHOLOGIA (2015)
CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores
Albader Albarmawi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections
Taotao Wang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections
Taotao Wang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
H. Ruth Ashbee et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing
Michael J. Dolton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics-Based Analysis of Adult Patients With Invasive Fungal Infections
Andres Pascual et al.
CLINICAL INFECTIOUS DISEASES (2012)
Bioavailability and Population Pharmacokinetics of Voriconazole in Lung Transplant Recipients
Kelong Han et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies
K. Nomura et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2008)
分享论文
